Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: <i>post-hoc</i> analysis of the SURMOUNT-5 trial
Authors
- Çağrı Şenyücel
- Harold Edward Bays (ORCID: https://orcid.org/0000-0001-9912-1408)
- Navneet Upadhyay (ORCID: https://orcid.org/0000-0003-3776-9596)
- Julia P. Dunn (ORCID: https://orcid.org/0000-0001-9561-0183)
- Tracy Irani (ORCID: https://orcid.org/0000-0003-1803-4359)
- Hong Liu‐Seifert (ORCID: https://orcid.org/0000-0002-9534-0483)
- Rui Li (ORCID: https://orcid.org/0000-0003-1329-9817)
- Mamas Mamas
Institutions
- Eli Lilly (United States) (US)
- Louisville Metabolic and Atherosclerosis Research Center (US)
- Keele University (GB)
Publication Details
- Journal
- European Heart Journal Open
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1093/ehjopen/oeaf117
- Citations
- 5
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 6.47